Cyclic peptides

Details Cyclic peptides Cyclic peptides

2007-11-19

2009-08-18

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S321000

Reexamination Certificate

active

07576057

ABSTRACT:
The invention relates to novel cyclic peptide derivatives of general formula (I):wherein A, B, R1and R2are as defined in the specification, pharmaceutically acceptable salts thereof, and their use as pharmaceuticals, in particular for the treatment of hepatitis C virus.

REFERENCES:
patent: 4639434 (1987-01-01), Wenger et al.
patent: 4703033 (1987-10-01), Sebach
patent: 4771122 (1988-09-01), Sebach
patent: 4798823 (1989-01-01), Witzel
patent: 4814323 (1989-03-01), Andrieu et al.
patent: 4885276 (1989-12-01), Witzel
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5122511 (1992-06-01), Patchett et al.
patent: 5169773 (1992-12-01), Rosenthaler et al.
patent: 5214130 (1993-05-01), Patchett et al.
patent: 5284826 (1994-02-01), Eberle
patent: 5294604 (1994-03-01), Nussenblatt
patent: 5489668 (1996-02-01), Morrison et al.
patent: 5639852 (1997-06-01), Rich et al.
patent: 5846964 (1998-12-01), Ozeki
patent: 5863550 (1999-01-01), Maeda et al.
patent: 5948693 (1999-09-01), Rich et al.
patent: 5948755 (1999-09-01), Barriere et al.
patent: 5948884 (1999-09-01), Lüchinger
patent: 5965527 (1999-10-01), Barriere et al.
patent: 5977067 (1999-11-01), Evers et al.
patent: 5981479 (1999-11-01), Ko et al.
patent: 5994299 (1999-11-01), Barriere et al.
patent: 6254860 (2001-07-01), Garst
patent: 6350442 (2002-02-01), Garst
patent: 6444643 (2002-09-01), Steiner et al.
patent: 6521595 (2003-02-01), Kim et al.
patent: 6583265 (2003-06-01), Ellmerer-Müller et al.
patent: 6924271 (2005-08-01), Averett et al.
patent: 6927208 (2005-08-01), Wenger et al.
patent: 7196161 (2007-03-01), Fliri et al.
patent: 2004/0077587 (2004-04-01), Sommadossi et al.
patent: 2004/0254117 (2004-12-01), Saksena et al.
patent: 2006/0025267 (2006-02-01), Gradu
patent: 2006/0089301 (2006-04-01), Fliri et al.
patent: 2006/0160727 (2006-07-01), Fliri et al.
patent: 2007/0173440 (2007-07-01), Houck
patent: 0 056 782 (1982-07-01), None
patent: 0 414 632 (1990-07-01), None
patent: 0 444 897 (1991-02-01), None
patent: 2 206 119 (1988-12-01), None
patent: WO 98/28328 (1998-07-01), None
patent: WO 98/28329 (1998-07-01), None
patent: WO 98/28330 (1998-07-01), None
patent: WO 99/32512 (1999-07-01), None
patent: WO 99/67280 (1999-12-01), None
patent: WO 00/01715 (2000-01-01), None
patent: WO 01/47883 (2001-05-01), None
patent: WO 2004/072108 (2004-08-01), None
patent: WO 2005/000308 (2005-01-01), None
patent: WO 2005/021028 (2005-03-01), None
patent: WO 2005/087798 (2005-09-01), None
patent: WO 2006/005610 (2006-01-01), None
patent: WO 2006/038088 (2006-04-01), None
patent: WO 2006/039668 (2006-04-01), None
patent: WO 2006/071619 (2006-06-01), None
patent: WO 2006/071618 (2006-07-01), None
patent: WO 2007/041631 (2007-04-01), None
patent: WO 2007/041632 (2007-04-01), None
Paechuyse et al. Potent and Selective Inhibition of Hepatitis C Virus . . . Antiviral Research. 2005, vol. 65, p. A41, Abstract No. 28.
European Patent Office, Standard Search Report, issued Sep. 10, 2007, for Application No. RS 115759; filed: Nov. 20, 2006.
Baumgrass et al., 2004, “Substitution in Position 3 of Cyclosporin A Abolishes the Cyclophilin-mediated Gain-of-function Mechanism but Not Immunosuppression,” Journal of Biological Chemistry, vol. 279(4):2470-2479.
Billich et al., 1995, “Mode of Action of SDZ NIM 811, a Nonimmunosuppressive Cyclosporin A Analog with Activity Against Human Immunodeficiency Virus (HIV) Type 1: Interference with HIV Protein-Cyclophilin A Interactions,” Journal of Virology, vol. 69(4):2451-2461.
Borel et al., 1977, “Effects of the New Anti-Lymphocytic Peptide Cyclosporin A in Animals,” Immunology, vol. 32:1017-1025.
Chan, et al., 2004, “Discovery of Thiophene-2-Carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 1: Sulfonamides,”Bioorganic&Medical Chemistry Letters, 14:793-796.
Chan, et al., 2004, “Discovery of Thiophene-2-Carboxylic Acids as Potent Inhibitors of HCV NS5B Polymerase and HCV Subgenomic RNA Replication. Part 2: Tertiary Amides,”Bioorganic&Medicinal Chemistry Letters, 14:797-800.
Colucci, et al., 1990, “Synthesis ofD-Lysine-cyclosporine A. Further Characterization of BOP-C1 in the 2-7 Hexapeptide Fragment Synthesis,” J. Org. Chem., vol. 55:2895-2903.
Cotler, Scott J., et al., 2003-04, “A Pilot Study of the Combination of Cyclosporin A and Interferon Alfacon-1 for the Treatment of Hepatitis C in Previous Nonresponder Patients,”Journal of Clinical Gastroenterology, vol. 36(4):352-355.
Cruz et al., 2000, “Immunosuppressive and Nonimmunosuppressive Cyclosporine Analogs Are Toxic to the Opportunistic Fungal PathogenCryptococcus neoformansvia Cyclophilin-Dependent Inhibition of Calcineurin,” Antimicrobial Agents and Chemotherapy, vol. 44(1):143-149.
Dhanak, et al., 2002, “Identification and Biological Characterization of Heterocyclic Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase,”Journal of Biological Chemistry, vol. 277(41):38322-38327.
DiMarco, et al., 2005, “Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site,”Journal of Biological Chemistry, vol. 280(33):29765-29770.
Eberle et al., 1994, “Cyclosporin A: Regioselective Ring Opening and Fragmentation Reactions via Thioamides. A Route to Semisynthetic Cyclosporins,” J. Org. Chem., vol. 59:7249-7258.
Evers et al., 2003, “Synthesis of Non-Immunosuppressive Cyclophilin-Binding Cyclosporin A Derivatives as Potential Anti-HIV-1 Drugs,”Bioorganic&Medicinal Chemistry Letters, vol. 13(24):4415-4419.
Gu, et al., 2003, “Arresting Initiation of Hepatitis C Virus RNA Synthesis Using Heterocyclic Derivatives,”Journal of Biological Chemistry, vol. 278(19):16602-16607.
Hansson et al., 2004, “The Nonimmunosuppressive Cyclosporin Analogs NIM811 and UNIL025 Display Nanomolar Potencies on Permeability Transition in Brain Derived Mitochondria,”Journal of Bioenergetics and Biomembranes, 36(4):407-413.
Hosmans, et al., 2004, “Isatoribine, A Toll-Like Receptor 7 Agonist, Significantly Reduced Plasma Viral Load in a Clinical Proof-of-Concept Study in Patients with Chronic Hepatitis C Virus Infection,”Hepatology, vol. 40:(4), Suppl. 1, Oct. 2004, 282A, No. 270.
Hubler et al., 2000, “Synthetic Routes to NEtXaa4-Cyclosporin A Derivatives a Potential Anti-HIV I Drugs,”Tetrahedron Letters, 41(37):7193-7196.
Inoue, K. et al., 2003, “Combined Interferon Alpha2b and Cyclosporin A in the Treatment of Chronic Hepatitis C: Controlled Trial,”Journal of Gastroenterology, Springer Verlag, Tokyo, JP, vol. 38(6):567-572.
Inoue et al., 2005, “Interferon Combined with Cyclosporin Treatment as an Effective Countermeasure Against Hepatitis C Virus Recurrences in Liver Transplant Patients with End-Stage Hepatitis C Virus Related Disease,”Transplantation Proceedings, 37(2):1233-1234.
Kallen et al., 1997, “12 Cyclosporins: Recent Development in Biosynthesis, Pharmacology and Biology, and Clinical Applications,” Biotechnology, 2ndEd. Completely Revised Edition, vol. 7, pp. 535-591.
Lamarre, et al., 2003, “An NS3 Protease Inhibitor with Antiviral Effects in Humans Infected with Hepatitis C Virus,”Nature, vol. 426:186-189.
LaPlante, et al., 2004, “Binding Mode Determination of Benzimidazole Inhibitors of the Hepatitis C Virus RNA Polymerase by a Structure and Dynamics Strategy,”Angew. Chem. Int., Ed. Engl., vol. 43:4306-4311.
Lee, et al., 2003, “Molecular Basis for the Immunostimulatory Activity of Guanine Nucleoside Analogs: Activation of Toll-Like Receptor 7,”PNAS, USA, vol. 100(11):6646-6651.
Lin, et al., 2005, “In Vitro Studies of Cross-Resistance Mutations Against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061,”Journal of Biological Chemistry, vol. 280(44):36784-36791.
Loor et al., 2002, “Cyclosporins: Str

Affiliated with

Also associated with

Rating

Cyclic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4099295